SCHEMBL487160

SCHEMBL487160

COc1cccc(P(c2cccc(OC)c2OC)c2cccc(OC)c2OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CA12 O43570 2/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA7 P43166 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ CA14 Q9ULX7 2/20 0.46
▸ CA4 P22748 1/20 0.46
▸ NFE2L2 Q16236 5/20 0.43
▸ HSD17B10 Q99714 3/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29402267 1.00 SMN1; SMN2 (0.48) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15658628 0.96 CA1 (0.48) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15659602 0.90 CA12 (0.43) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15659282 0.89 CA1 (0.41) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15659746 0.87 SMN1; SMN2 (0.39) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL6833825 0.86 NFE2L2 (0.45) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL6841051 0.86 NFE2L2 (0.45) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15658213 0.84 SMN1; SMN2 (0.37) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15656480 0.81 CA12 (0.41) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL15658832 0.81 SMN1; SMN2 (0.48) SMN1; SMN2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652104-B2 Epoxy resin composition KURARAY CO., LTD. (JP) 2010-01-26 — — US claimed
EP-1651704-A1 COATING COMPOSITIONS CONTAINING AMINOFUNCTIONAL SILICONE RESINS Dow Corning Corporation (US) 2006-05-03 — — EP claimed
WO-2005010078-A1 COATING COMPOSITIONS CONTAINING AMINOFUNCTIONAL SILICONE RESINS DOW CORNING CORPORATION (US) 2005-02-03 — — WO claimed
JP-3239718-A — — None — — JP disclosed
JP-11286625-A — — None — — JP disclosed
EP-3756203-B1 ENCAPSULATED SUPERCAPACITOR MODULE HAVING A HIGH VOLTAGE AND LOW EQUIVALENT SERIES RESISTANCE KYOCERA AVX COMPONENTS CORP (US) 2026-04-01 — — EP disclosed
EP-3756202-B1 ELECTRICAL CIRCUIT INCLUDING A SUPERCAPACITOR WITH REDUCED LEAKAGE KYOCERA AVX COMPONENTS CORP (US) 2026-01-28 — — EP disclosed
US-20250109222-A1 CYCLIC ORGANOSILOXANE CONTAINING IMIDE BOND AND POLYMERIZABLE UNSATURATED BOND, AND CURABLE RESIN COMPOSITION COMPRISING SAID CYCLIC ORGANOSILOXANE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-04-03 — — US disclosed
US-12230442-B2 Surface mountable ultracapacitor device including a resin layer having vents KYOCERA AVX Components Corporation (US) 2025-02-18 — — US disclosed
US-20240425677-A1 CURABLE COMPOSITION CONTAINING RICE HUSK ASH BIOSILICA TOUGHENED EPOXY RESIN Najran University (SA) 2024-12-26 — — US disclosed
WO-2024207393-A1 AQUEOUSLY DISPERSED EPOXY RESIN COMPOSITION, PAINT, AND ARTICLE DIC CORPORATION (JP) 2024-10-10 — — WO disclosed
EP-0286196-A2 Preparation of substituted diaryl phosphides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-10-12 — — EP disclosed
US-4746707-A DIENE-NITRILE COPOLYMERS USING A RUTHENIUM COMPLEX CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1988-05-24 — — US disclosed
EP-0138141-B1 PROCESS FOR THE SELECTIVE HYDROGENATION OF C-C DOUBLE BONDS IN THE PRESENCE OF REDUCIBLE NITROGEN-CONTAINING GROUPS BAYER AG (DE) 1988-02-24 — — EP disclosed
US-4673757-A Process for selective hydrogenation of C-C double bonds in the presence of reducible, nitrogen-containing groups and new ruthenium complex compounds BAYER AKTIENGESELLSCHAFT (DE) 1987-06-16 — — US disclosed
EP-0213422-A2 Process for the selective hydrogenation of unsaturated compounds BAYER AG (DE) 1987-03-11 — — EP disclosed
US-4631315-A RUTHENIUM HALOGEN PHOSPHANE COMPLEX CATALYST TO PRESERVE NITRILE GROUPS; RUBBERS BAYER AKTIENGESELLSCHAFT (DE) 1986-12-23 — — US disclosed
EP-0174576-A2 Hydrogenation of unsaturated polymers containing nitrile groups BAYER AG (DE) 1986-03-19 — — EP disclosed
EP-0138141-A1 Process for the selective hydrogenation of C-C double bonds in the presence of reducible nitrogen-containing groups BAYER AG (DE) 1985-04-24 — — EP disclosed
US-4034004-A AND CARBON MONOXIDE, PHOSPHINE PALLADIUM COMPLEX AS CATALYST MONTEDISON FIBRE S.P.A. (IT) 1977-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109222-A1 CYCLIC ORGANOSILOXANE CONTAINING IMIDE BOND AND POLYMERIZABLE UNSATURATED BOND, AND CURABLE RESIN COMPOSITION COMPRISING SAID CYCLIC ORGANOSILOXANE ZYX, MUS81, H1-0 SMN1; SMN2 357/4885CA12 2533/4885CA1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback